Building an Assessment Model for Vitiligo Activity and Prognosis Using Peripheral Blood Cytokine Profiles
A legfontosabb adatok
- Ki végzi
- Xijing Hospital
- Hol
- Xi'an (Kína)A helyszín megnézése
- Azonosító
- Állapot
- Toborzás még nem indult
- Résztvevők
- 125 fő, tervezett
- Kezdés
- 2025. dec. 23.
- Várható befejezés
- 2027. szept. 1.
- A vizsgálat típusa
- Megfigyeléses, 2 csoport
- A vizsgált kezelések
- Serum Cytokine Assay
- A regiszteradat frissítve
- 2025. december 23.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with confirmed vitiligo, plus a group of healthy people for comparison. Blood tests will measure 12 cytokines (immune signal proteins).
- Életkor
- 18 Years to 80 Years
- Nem
- All sexes can join.
- A betegség stádiuma
- Vitiligo confirmed by a doctor, using the 2018 Chinese consensus criteria. Healthy people can also join as a control group.
- Korábbi kezelés
- People who used antibiotics, corticosteroids or immunosuppressants within the past month cannot join.
A részvétel fő kizáró okai
- Severe heart, blood vessel or brain blood vessel disease, severe diabetes, severe infection, or other major illness causing poor physical condition
- Light-sensitivity disorders, skin tumors, autoimmune diseases or blood disorders
- Pregnant or breastfeeding women
- Poor psychological stability, or unable to keep follow-up visits or nursing care
- Less than elementary school education
A regiszter feltételei, szó szerint
Mind a 9 feltétel megnézéseKevesebb
Ki vehet részt
- Patients with clinically confirmed vitiligo (diagnosis criteria refer to the Consensus on Vitiligo Diagnosis and Treatment (2018 Edition) established by the Pigment Disorders Group of the Dermatology and Venereology Professional Committee of the Chinese Association of Integrative Medicine) and a healthy control group
- Aged 18 years or older, no gender restrictions
- Possess an elementary school education or higher
- Voluntarily participate in this study
Ki nem vehet részt
- Patients who have used antibiotics, corticosteroids, or immunosuppressants within the past month
- Patients with severe cardiovascular or cerebrovascular disease, severe diabetes, severe infection, or other major illnesses resulting in poor physical condition
- Patients with photosensitive disorders, skin tumors, autoimmune diseases, or hematological disorders
- Pregnant or lactating women
- Patients with poor psychological stability or compliance who cannot cooperate with follow-up visits or nursing care
A fő feltételek kérdésként
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 18 és 80 év között vagy?
Helyszínek itt: Kína
- Xijing hospitalXi'an, KínaContact: Jian Zhe, Associate ProfessorToborzás még nem indult
A vizsgálatról
Mit akar kideríteni a vizsgálat
Vitiligo is a chronic autoimmune disorder characterized by depigmented patches on the skin, which can pose significant psychosocial challenges, particularly for individuals with darker skin tones. Compared to the general population, individuals with vitiligo are more likely to experience immune-mediated diseases or psychological comorbidities. Studies confirm that the combined prevalence of depression and anxiety among vitiligo patients reaches 8% and 35.8%, respectively. Notably, the anxiety prevalence rate is comparable to that seen in other severely debilitating skin conditions such as eczema and psoriasis. However, the progression, stability, and recurrence of vitiligo exhibit high unpredictability. Unlike other inflammatory skin diseases such as psoriasis or atopic dermatitis, there is currently a lack of objective, sensitive biological markers in clinical practice to predict disease activity, forecast treatment response, or assess long-term prognosis. Decisions primarily rely on the attending physician's assessment of disease activity, affected areas, severity, and repigmentation potential. Furthermore, clinical signs of active vitiligo are only observable in some active-phase patients, introducing delays and subjectivity. This leads to reactive treatment decisions, increasing the likelihood of missing the optimal intervention window. Cytokines are small-molecule polypeptides or glycoproteins synthesized and secreted by the body's cells, possessing diverse biological activities. They play a central role in physiological and pathological processes such as immune regulation, anti-infection, and anti-tumor responses. The "Twelve Cytokine Panel" is a clinical test utilizing advanced flow cytometry for the combined analysis of 12 core cytokines. The cytokines included in this test are IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, IL-17, IFN-α, IFN-γ, and TNF-α. This panel comprehensively reflects innate immune and T-cell immune responses, providing crucial laboratory evidence for evaluating the functional status of the immune system and inflammatory network. Cytokines serve as core messenger molecules in the autoimmune pathogenesis of vitiligo, forming a complex inflammatory network that governs the entire process of immune attacks against melanocytes. Consequently, detecting specific cytokine profiles not only deepens our understanding of vitiligo's disease mechanisms but also holds immense potential clinical value in assessing disease activity, monitoring treatment efficacy, and developing novel targeted therapies.
A vizsgálat 2 csoportja
- healthy people
Kezelés: Serum Cytokine Assay
- vitiligo patients
Vitiligo patients were assigned to one of the following treatment groups based on clinical protocols: topical therapy group, systemic therapy group, phototherapy group, or combination therapy group.
Kezelés: Serum Cytokine Assay
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Construction of an Assessment Model for Vitiligo Disease Activity and Treatment Prognosis Based on Peripheral Blood Cytokine Profiles
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- Kérdések a feltételekről
- Forrás: NCT07298551: ki vehet részt
- A regiszteradat frissítve
- 2025. december 23.